SK Hynix Shares Fall as Workers Reject Wage Deal 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Tesla Raises Cybertruck Prices by $5,000 in US 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Nvidia Options Price in $280 Billion Earnings Swing 
Add as a preferred source on Google
VANCOUVER, British Columbia, April 26, 2018 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, announced today that David Main, President & CEO, will provide a corporate update at the upcoming 2018 Bloom Burton & Co. Healthcare Conference in Toronto on Thursday, May 3rd 2018.
Aquinox Presentation Details
Date: Thursday, May 3rd 2018
Time: 7:30 am Pacific Time / 10:30 am Eastern Time
Location: Toronto, ON – Sheraton Centre Hotel Toronto
A live audio webcast and archive of the event will be available at:
http://wsw.com/webcast/bloomburton3/aqxp/
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics for chronic urological conditions marked by inflammation and pain. Aquinox's lead drug candidate, rosiptor (AQX-1125), is in Phase 3 development for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS), a condition for which there are currently few FDA approved and/or effective treatment options. Aquinox is focused on leveraging its library of novel compounds that activate SHIP1 to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. For more information, please visit http://www.aqxpharma.com/.
Investor Contact Info:
Brendan Payne
Associate Director, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.901.3019
[email protected]
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
[email protected]
